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B enzodiazepine and SSHs have sedative, hypnotic, anxiolytic, muscle relaxant, and anticonvulsant properties. In addition to their therapeutic properties, BDZ-SSHs are associated with adverse effects, including cognitive problems, 1, 2 an increased risk of falls, [3] [4] [5] [6] an increased frequency of motor vehicle accidents, [7] [8] [9] and dependence and abuse. 10, 11 For the most part, the pharmacoepidemiologic literature is restricted to estimates of the prevalence and cross-sectional correlates of BDZ-SSH use. [12] [13] [14] For example, the ESEMeD found that anxiety and depressive disorders, female sex, older age, help seeking for emotional problems, low education, and pain predicted BDZ use in 6 European countries. 15 Similarly, in Canada, cross-sectional correlates of BDZ use include female sex, (higher) age, low income, low education, and the presence of mood or anxiety disorders. 13 Few longitudinal studies have examined BDZ use in Canada.
Zopiclone (a cyclopyrrolone derivative) and zaleplon (a pyrazolopyrimidine) are non-BDZ-SSHs that share pharmacological properties, adverse effects, and risks with BDZ. 10, 16, 17 However, these medications are used more specifically for insomnia and less frequently for anxiety. Both zopiclone and zaleplon are listed under Schedule IV by the International Narcotics Control Board. 18 However, neither zopiclone nor zaleplon are classified as controlled drugs in Canada, whereas BDZs are.
Treatment with BDZ-SSHs is often initiated during treatment of depressive disorders, particularly when symptoms of anxiety are present. 19 Such use is often intended to be brief, with discontinuation of the BDZ-SSH being intended when a coprescribed AD begins to work. Some courses of BDZ-SSH treatment may become prolonged if there are residual symptoms of depression or comorbidities that lead to longer-term treatment. Some ADs, may cause insomnia or agitation as an adverse effect and this may also lead to an increased or more prolonged coprescribing of BDZ-SSHs. Tolerance and abuse may also lead to prolonged BDZ-SSH exposure. The objectives of our study included estimation of the incidence and pattern of new use and the frequency and pattern of discontinuation of BDZ-SSH medications in relation to MDEs and the use of ADs.
Method
The NPHS is a longitudinal study based on a nationally representative sample of 17 276 respondents selected from the Canadian household population by Statistics Canada in 1994. The NPHS longitudinal cohort has been interviewed every 2 years since that time. The NPHS methodology is described in previous publications. 20 The estimated response rate to 2006 is 77.0%. 20 This response rate does not include NPHS respondents who left the sampling frame (died or were institutionalized) during follow-up as they were considered to have been successfully followed. The 1994 baseline interviews were conducted in person (75%), but 99% of follow-up interviews were conducted over the phone.
The NPHS interview includes items covering demographics, health status, health care use, and health determinants. Respondents were also asked to retrieve containers (boxes, bottles, tubes, or packages) of medications taken in the 2 days preceding an interview. Specific medications were recorded using ATC codes. These ATC codes were used in the current analysis to identify respondents who were taking a BDZ-SSH and to identify the use of ADs. We examined the incidence of new use of BDZ-SSH as the frequency of reported use at subsequent cycles after not reporting use at an initial cycle. A particular concern is the pattern of persistent BDZ-SSH use, as this may be more problematic than short-term use. An analysis was therefore performed requiring 2 consecutive cycles of new use. As the patterns of initiation and discontinuation may differ depending on the type of medication, additional analyses were performed in which zopiclone and zaleplon were analyzed separately from BDZ. As the 2-day record of use covers a brief period of time, we also examined (for comparative purposes) the incidence of use of sleeping pills in the preceding month, as documented by responses to a different item: "In the past month, did you take sleeping pills?"
To examine trends in the frequency of BDZ-SSH use, we initially tabulated unadjusted frequencies by year of interview. We also tabulated the types of medications used and the frequency of use of more than one BDZ-SSH at the same time.
To examine the impact of ADs and MDEs on initiation and discontinuation of BDZ-SSHs, we used discrete (grouped) time proportional hazard models to estimate HRs. These models included both age and sex to generate estimates of the effect of ADs and MDE on subsequent BDZ-SSHs adjusted for these nonmodifiable determinants of use. We also developed models incorporating additional potential determinants to assess possible confounding effects. As we were interested in the effects of AD use on subsequent BDZ-SSH use, AD use was incorporated into these models as a time-varying covariate. Where applicable, other covariates were also allowed to vary over time. These included self-reported professionally diagnosed painful conditions (migraine, injury, or back pain), employment status, education level, alcohol consumption, smoking, and income. Employment status was dichotomized into working, compared with not working, status. Education was categorized according to whether a respondent had more or less than secondary level education. Excessive alcohol consumption was classified using self-report items in which consumption of 5 or more drinks on a single occasion was recorded. Smoking was categorized by distinguishing between current smokers and nonsmokers, with the latter category including both former and never-smokers. In the analysis concerned with initiation of use, we also included a variable that was intended to represent a general propensity to access health services as such propensity could plausibly be a determinant of exposure to BDZ-SSH. For this purpose, we used counts of past-year visits to general practitioners or family physicians, categorizing these counts as 1, 2, or 3 or more visits. Terms representing interactions between the predictive variables and time-period indicator variables were used to evaluate the proportional hazards assumption. Statistical significance was evaluated using likelihood ratio tests for the set of relevant interaction terms.
Other P values reported in the paper derive from Wald tests.
The NPHS interview included the CIDI-SFMD, 21 which assesses past-year MDE. The CIDI-SFMD is scored with a predictive probability algorithm based on the number of symptom-based criteria fulfilled during a 2-week period in the year preceding the interview. The instrument was scored at the 90% predictive probability level, indicating endorsement of 5 symptoms.
The approach to scoring of the CIDI-SFMD is broadly consistent with the DSM-IV A criterion requirement for MDE. 22 However, the CIDI-SFMD was originally validated against DSM-IIIR criteria. 21 The scoring algorithm stipulates that at least one of these symptoms must be depressed mood or loss of interest or pleasure, also broadly consistent with DSM-IV.
The NPHS used a stratified multistage sampling procedure. Replicate sampling weights provided by Statistics Canada and an associated bootstrap procedure for variance estimation were used to account for design effects. All analyses were conducted using Stata 23 at the Prairie Regional Data Centre on the University of Calgary Campus. Our study was approved by the University of Calgary Conjoint Health Research Ethics Board.
Results
Among the 17 276 respondents in the NPHS longitudinal file, 15 254 were considered eligible for this analysis because they were aged 13 years and older at the baseline interview. Consistent with prior reports, 13 the frequency of prevalent BDZ-SSH use was between 2% and 3% at each NPHS cycle, with no clear trend suggesting an increasing or decreasing frequency of use ( Figure 1) . A detailed description of the disposition of the sample is provided in Figure 2 . When the sample was restricted to 7780 respondents with completed interviews at each of the 7 NPHS cycles from 1994 to 2006 (this includes some respondents with partial responses), 90% reported no BDZ-SSH use at any cycle. A small proportion (less than 0.5%) reported use at each of the 7 NPHS cycles ( No violations of the proportional hazard assumption were found. In unadjusted analyses, AD use was strongly predictive of initiation of BDZ-SSHs (unadjusted HR 3.8, 95% CI 2.9 to 4.9). In a proportional hazard model including MDE, age, sex, and interaction terms, a sex by MDE interaction was identified (HR for the interaction term 0.3, 95% CI 0.1 to 0.7, P = 0.006). In men, the age-adjusted HR for ADs was 4.6 (95% CI 1.8 to 11.6) and for MDE was 8.4 (95% CI 3.6 to 19.7), whereas in women these HRs were 6.8 (95% CI 4.4 to 10.5) and 2.2 (95% CI 1.3 to 3.9), respectively. Table 2 presents a model incorporating a broader set of covariates. As expected, age and sex were associated with initiation of BDZ-SSH, as were pain complaints, smoking, and having 3 or more primary care visits in the past year. These adjustments attenuated the associations of MDE and AD use with BDZ-SSHs, but the associations remained evident and were statistically significant. There were no significant interactions involving sex, but there was an interaction between MDE and age, with the effect of MDE being smaller in people aged 66 years and older. The model presented in Table 2 Pharmacoepidemiology does not include covariates that were not significantly associated with new BDZ-SSH use. Inclusion of these additional variables in more complex models did not lead to substantial changes in the HRs.
With application of the persistent use definition (new use on 2 consecutive cycles), the associations for ADs and MDE persisted with covariate adjustments. In men, after adjustment for age, general practitioner visits, and pain (the only covariates continuing to attain significance in this analysis) the HR for AD use was 3.6 (95% CI 1.9 to 6.6) and for MDE was 5.7 (95% CI 3.2 to 10.1). Inclusion of additional covariates did not substantially change the HR estimates. In women, the adjusted HRs were 5.4 (95% CI 3.4 to 8.4) for ADs and 1.9 (95% CI 1.1 to 3.3) for MDE. Examining new BDZ use (excluding zopiclone and zaleplon), the results were broadly comparable: the age adjusted HR for AD use in men was 3.5 (95% CI 1.6 to 7.5), whereas MDE was 3.3 (95% CI 1.8 to 6.1). In women, the age adjusted HR for AD use was 2.5 (95% CI 1.7 to 3.7) and for MDE was 1.4 (95% CI 0.9 to 2.2), the latter effect did not achieve statistical significance (P = 0.16). Using zopiclone or zaleplon use as the outcome variable (excluding BDZs), the age and sex adjusted HRs in this analysis were 2.6 (95% CI 1.6 to 4.4) for AD use and 2.6 (95% CI 1.6 to 4.4) for MDE.
A concern is the possibility that the past 2-day approach to measurement would result in a lack of specificity for new use as sporadic users may be detected if they happen to take a medication in the 2 days preceding the interview. As noted above, the frequency of self-reported past-month sleeping pill use was about twice as high as that for ATC coded (past 2-day)
BDZ-SSH use. To assess whether this resulted in a distortion of the epidemiologic results, we modelled the determinants of new self-reported sleeping pill use, incorporating various covariate adjustments. The results were similar to those reported above. For example, the HR for AD use, adjusted for age and sex was 2.7 (95% CI 2.1 to 3.5) and that for MDE was 2.1 (95% CI 1.7 to 2.8).
The next part of the analysis focused on discontinuation of BDZ-SSHs. The analysis of discontinuation included 429 respondents who reported taking a BDZ-SSH at the baseline interview. The frequency with which these respondents continued their BDZ-SSHs during the next 2 years was 54.5% (95% CI 47.8% to 61.1%). However, among those who also reported use in 1996, only 44.5% (95% CI 35.5% to 53.6%) continued use during the subsequent 2-year cycle. Figure 3 shows the proportion taking a BDZ-SSH at each cycle among people who reported use of BDZ-SSH at the initial interview in 1994. Although these estimates are imprecise, the probability of discontinuation appears to decline with increasing duration of use. A similar pattern was observed in the analysis of self-reported sleeping pill use. Sample size limitations precluded an analysis of the non-BDZ medications.
ADs are likely candidates for increasing the rate of BDZ-SSH discontinuation because of their effectiveness in the treatment of mood and anxiety disorders. A proportional hazard model, including an indicator variable for AD use, MDE as a time-varying characteristic, sex, and age was used to evaluate this possibility. In this model, AD use was not associated with discontinuation (HR 0.8, 95% CI 0.4 to 1.5), nor was MDE (HR 0.8, 95% CI 0.5 to 1.5). Sex was also not associated with probability of discontinuation (HR 1.1, 95% CI 0.7 to 1.8). HRs comparing the group aged 46 to 65 years (HR 1.0, 95% CI 0.5 to 1.9) and the group aged 66 years and older (HR 1.4, 95% CI 0.7 to 2.5) to the baseline (45 years and younger) age group did not suggest an effect of age on the discontinuation pattern. Nearly identical results were seen when past-month sleeping pill use was evaluated using the same approach. In our study, the HR for AD use was 0.8 (95% CI 0.4 to 1.6).
Discussion
The results presented in our study extend an existing, largely cross-sectional, literature about the pharmacoepidemiology of BDZ-SSH use. Prevalent use of BDZ-SSH arises as a steady-state outcome of new use, discontinuation of use, and associated mortality in the population. The longitudinal data available in the NPHS cannot conclusively delineate the balance between these factors because the data collected do not reconstruct a full record of medication use in the 2 years between interviews. However, the NPHS does provide a general perspective on the pattern of use. In the general household population not taking a BDZ-SSH, 1.0% to 1.3% were found to be taking one of these medications 2 years later. Among those taking an AD, about one-half were no longer taking them 2 years later. Among the 2% to 3% of the population taking BDZ-SSH, a sizable proportion (about one-third) appear to have initiated use within the preceding 2 years and a sizable proportion (about one-half) appear to discontinue over the next 2 years. A smaller proportion have a pattern of highly persistent use, but these can be expected to accumulate to a great extent in the pool of prevalent BDZ-SSH users.
BDZ-SSHs are frequently used in conjunction with ADs for symptom management early in the course of treatment for depressive disorders. ADs and BDZ-SSHs may also be used in combination for the management of anxiety disorders. Clinical expectation holds that the risk of long-term BDZ-SSH use should be diminished if patients receive effective treatment for underlying mood or anxiety disorders. Unexpectedly, the analysis found that respondents taking ADs had a higher risk of BDZ use, even after adjustment for MDE. It is conceivable that AD side effects may contribute to this pattern, as some ADs may trigger insomnia, agitation, or anxiety as adverse effects. However, it is also possible that respondents receiving treatment both with ADs and BDZ-SSH have more severe illness and that residual symptoms (such as insomnia or anxiety) are more likely to persist after partial resolution of MDE. Another possibility is that even when patients respond to an AD the BDZ-SSH may not be discontinued, either because of rebound symptoms or because of hesitancy on the part of physicians to alter a successful combination. Finally, ADs may sometimes be used in an attempt to treat insomnia, which may subsequently lead to hypnotic exposure. Such effects cannot be disentangled using the NPHS data, but it is clear that patients taking ADs are at an elevated risk of persistent BDZ-SSH use. In other words, ADs are an indicator of risk for subsequent BDZ-SSH use. The NPHS has additional limitations. The measure of MDE is a brief predictive measure that is not expected to be as accurate as the full version of the CIDI instrument. Inaccurate measurement often diminishes the strength of association observed in epidemiologic studies. 24 Assessment of BDZ-SSH use during the 2 days preceding an interview is a sensitive indicator of continuous use, but is not specific for continuous use. Some patients with sporadic use will also be detected. Infrequent sporadic use would be less likely to influence the analysis than more frequent use. For example, a person taking BDZ-SSH on 10% of days would have an 81% chance of being classified as a nonuser at the baseline assessment and to therefore be considered eligible for inclusion in the initiation of use analysis. The same respondent has a 19% chance of being classified as a BDZ-SSH user at a follow-up interview. If these events are independent, the respondent would have a 15% chance of being misclassified as a new user. However, this would fall to 3% in the part of the analysis requiring 2 consecutive cycles with use. While such misclassification could bias the frequency estimates upward, it would be more likely to bias the HRs toward the null value of one through a process of dilution. The comparability of results for past-month sleeping pill use helps to confirm that such misclassification was not a major source of bias.
The NPHS does not include an assessment of anxiety disorders, such that the role of these disorders in determining BDZ use cannot be clarified. An additional comorbidity that is not assessed in the NPHS is BDZ dependence. A lack of detailed clinical information about these comorbid conditions means that the results reported here should not be interpreted as an assessment of the clinical appropriateness of BDZ-SSH use. For example, some patients with long-term use may achieve positive outcomes, whereas others may encounter negative outcomes from short-term use. The estimates presented here provide a description of the overall epidemiologic pattern rather than an assessment of the appropriateness of any particular pattern of use.
The proportion of respondents taking BDZ-SSHs who no longer reported doing so in subsequent cycles declines with the duration of use (Figure 3 ). This pattern is consistent with, but does not provide conclusive evidence for, the emergence of tolerance to BDZ-SSHs. The proportion of respondents who reported taking these medications throughout follow-up was small, suggesting that continuous multi-year use of these medications is uncommon. However, it may be noted that this part of the analysis excluded many elderly respondents who were removed from the sampling frame owing to death or institutionalization during the 12 years of follow-up. Highly persistent use may be more common in this older age group.
ADs are more decisive and effective treatments for mood and some anxiety disorders than BDZ-SSH. Expectation holds that with the onset of activity of an AD, discontinuation of a BDZ-SSH should usually be feasible owing to the expected improvement in sleep and other symptoms. However, the epidemiologic data presented here indicate that AD-treated patients have an elevated risk of persistent BDZ-SSH use. It will be important to determine whether this is due to problems in service delivery (for example, failure to follow through with plans to discontinue the medications), to residual symptoms, to tolerance or rebound effects, BDZ abuse, or dependence, or to an offsetting of therapeutic benefits by AD-related adverse effects.
Résumé : Pharmaco-épidémiologie de l'utilisation des benzodiazépines et des sédatifs-hypnotiques dans une cohorte de la population générale canadienne durant 12 ans de suivi
Objectif : Les benzodiazépines (BDZ) et les sédatifs-hypnotiques semblables (SHS) peuvent avoir des effets tant bénéfiques qu'indésirables. Les guides de pratique clinique indiquent que le cours du traitement devrait habituellement être bref (quelques semaines), mais les patients prennent souvent ces médicaments pendant de plus longues périodes. Nous avons émis l'hypothèse que le traitement aux antidépresseurs (AD) serait associé à une utilisation de SHS de plus courte durée car les troubles de l'humeur et anxieux peuvent être sous-jacents aux symptômes habituellement ciblés par le traitement aux BDZ.
Méthode : Notre étude a utilisé les données d'une étude longitudinale canadienne sur la santé générale, l'Enquête nationale sur la santé de la population (ENSP), qui recueille des données depuis 1994. Les données présentement disponibles sont celles de 2006. À chaque entrevue, tous les médicaments pris dans les 2 jours précédents ont été enregistrés. Dans notre étude, nous avons utilisé des modèles à risques proportionnels pour décrire les tendances de l'initiation et de la cessation de ces médicaments dans la population générale.
Résultats : À chaque entrevue, la fréquence d'utilisation des BDZ-SHS était de 2 % à 3 %. Environ 1 % de la population initiait l'utilisation à chaque période de suivi de 2 ans. Contrairement à nos prévisions, le fait de prendre des AD prédisait l'initiation des BDZ-SHS, mais pas la cessation.
Conclusions : Étonnamment, les répondants prenant des AD avaient une fréquence plus élevée d'utilisation nouvelle des BDZ-SHS. L'utilisation d'AD peut être un marqueur de la gravité ou de la comorbidité de la dépression, de sorte que les résultats observés peuvent être un artéfact de confusion par ces facteurs. Sans égard à l'étiologie, l'initiation du traitement aux AD ne semble pas annuler le risque d'une utilisation à long terme des BDZ-SHS.
